PDT Partners’s Neurocrine Biosciences NBIX Stock Holding History

PDT Partners’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.79M	Hold	28,781	–	–	0.22%	152
2025 Q4	$4.08M	Sell	28,781 -12,823	-31%	-$1.86M	0.26%	136
2025 Q3	$5.84M	Sell	41,604 -1	-0%	-$135	0.37%	73
2025 Q2	$5.23M	Buy	41,605 +23,200	+126%	+$2.66M	0.3%	96
2025 Q1	$2.04M	Sell	18,405 -16,343	-47%	-$2.07M	0.14%	247
2024 Q4	$4.74M	Buy	34,748 +19,848	+133%	+$2.45M	0.42%	39
2024 Q3	$1.72M	Buy	+14,900	New	+$2.04M	0.15%	249
2023 Q4	–	Sell	-9,306	Closed	-$1.05M	–	630
2023 Q3	$1.05M	Sell	9,306 -1,206	-11%	-$127K	0.13%	273
2023 Q2	$991K	Buy	+10,512	New	+$1.03M	0.14%	250
2022 Q4	–	Sell	-8,255	Closed	-$877K	–	803
2022 Q3	$877K	Buy	+8,255	New	+$838K	0.13%	258
2015 Q4	–	Sell	-48,088	Closed	-$1.91M	–	749
2015 Q3	$1.91M	Sell	48,088 -400	-0.8%	-$19.3K	0.04%	475
2015 Q2	$2.32M	Buy	48,488 +36,975	+321%	+$1.57M	0.06%	380
2015 Q1	$457K	Buy	+11,513	New	+$412K	0.01%	1048
2013 Q3	–	Sell	-23,788	Closed	-$318K	–	1639
2013 Q2	$318K	Buy	+23,788	New	+$292K	0.01%	1238

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PDT Partners's NBIX Position: Q1 2026 in Review

PDT Partners held its Neurocrine Biosciences (NBIX) position steady in Q1 2026 at 28,781 shares worth $3.79M. The position accounts for 0.22% of the portfolio, ranked #152.

PDT Partners first reported a position in NBIX in Q2 2013 and has held it in 14 quarters since. The position peaked at $5.84M in Q3 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

PDT Partners held 28,781 shares of Neurocrine Biosciences worth $3.79M as of Q1 2026.
PDT Partners left its Neurocrine Biosciences share count unchanged in Q1 2026.
Neurocrine Biosciences made up 0.22% of PDT Partners's portfolio in Q1 2026, its #152 holding.
PDT Partners first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 14 quarters since.
PDT Partners's Neurocrine Biosciences position peaked at $5.84M in Q3 2025.
695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on PDT Partners's 13F filing for Q1 2026, filed 15 May 2026.